• Skip to main content
  • Skip to footer
cnb1383_liver-model-drug-safety_webinar_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Immune-mediated liver injury

How can you predict immune-mediated liver injury following drug dosing?


Immune-mediated liver injury is caused by activation of inflammatory pathways, making the liver more sensitive to insults. In particular, new modality drugs, such as monoclonal antibodies, can activate the peripheral immune system to initiate a cascade of liver damage. 

Immune-mediated liver injury is currently challenging to predict as the cause of the hepatic injury is often complex, interaction-based, and situation-specific. Therapeutics that act via the immune system, such as monoclonal antibodies for cancer, can under- or over-activate the immune system, causing increased autoimmunity or reactivation of liver viruses such as hepatitis B. 

Traditional in vitro models do not facilitate the co-culture of liver cells with circulating immune cells, provide the longevity to explore chronic inflammation effects or enable the impact of underlying disease states on immune-mediated liver injury to be evaluated. In vivo models have unique immune systems which do not naturally recapitulate humans. In addition, stress from living in the laboratory setting and research can significantly impact metabolism, inflammatory responses and disease progressions. 

Our solution

By incorporating immune cells into PhysioMimix® Liver-on-a-chip models, detailed mechanistic studies of the condition in the presence of various inflammatory cues and disease can now be performed to flag the immune-mediated liver injury risk of small molecules or biologics.

The tissue-resident macrophages of the liver (Kupffer cells) are cocultured with primary human hepatocytes to determine liver-specific inflammatory response as part of our PhysioMimix Drug-induced liver injury (DILI) assay. 

Additionally, by including peripheral immune cells into the circulating media of the Liver-12 plate, it is possible to determine interactions between the immune system and the liver to identify adverse effects on hepatic health, function or changes to the inflammatory profile. 

Using PhysioMimix disease models, drugs can also be tested against common liver disorders such as Hepatitis B and MASLD/MASH to identify patient cohorts with increased DILI susceptibility due to underlying inflammatory disease.

These capabilities enable you to future-proof your testing workflows in response to the FDA’s plans to phase out the animal testing requirement for monoclonal antibodies and other drugs with more human-relevant models. We are currently looking for partners to further validate the assay. Please contact us if you would like to participate.

Immune-mediated toxicity cells

Studying immune-mediated liver injury

Limitations with current techniques

  • Challenging to study immune-tissue level interaction in vitro
  • Poor in vitro to in vivo data translation
  • Unable to recapitulate inflammation driven by disease
  • Challenging to run acute and chronic exposure assays due to short-lived cultures

Advancements with PhysioMimix OOC

  • Immune cells can be incorporated into and circulate around liver microtissues
  • Measurement of clinical biomarkers (e.g. ALT/AST) allows for direct comparison to in vivo data
  • Inflammation can be induced through disease state, e.g. MASLD/MASH
  • Long-term stable tissues enable repeat compound dosing

End point measurements


Longitudinal and endpoint measurements include (but not limited to):

Functionality biomarkers

  • Cytochrome P450 enzyme activity
  • Albumin production
  • Urea production
  • Cytokine/chemokine release

Clinical liver health biomarkers

  • Lactose dehydrogenase (LDH) release
  • Adenosine Triphosphate (ATP)
  • Aspartate Transferase (AST)/Alanine amino transferase (ALT)

Optional profiling analysis

  • Quantitative PCR
  • Transcriptomics
  • Flow cytometry

Discern immune-mediated liver injury


Following exposure to pro-inflammatory stimuli, liver microtissues produce a range of physiologically relevant cytokines, chemokines, and growth factors that can be altered using different stimuli or inducing disease states.

Sarkar et al., 2017

Immune-mediated toxicity graph

Flagging enhanced DILI risk due to inflammation


The effect of inflammation on DILI sensitivity is assessed by testing therapeutics with or without specific immunomodulators (e.g., LPS).

Rubiano et al., 2020

Kupffer cells bar graph
image004 | immune-mediated liver injury

Detect immune-organ inflammatory events


Include peripheral immune cells and measure multiple soluble markers over time to understand interactions between multiple organs during inflammatory adverse events. Detect acute phase response proteins, like albumin and C-reactive protein (CRP), and predict cytokine storm events. 

image 05 | immune-mediated liver injury
image 06 1 | immune-mediated liver injury

Explore our Liver-on-a-chip models


Recreate the 3D multi-cellular architecture of the liver using perfused scaffolds. Achieve longer-term viability, enhanced functionality & high metabolic activity.

Learn more

Access our DILI Service


Get instant access to the immune-mediated DILI Assay via our CRO Service. Through a collaborative approach, our experts work with you to plan and execute your study.

Bespoke projects are carried out by our dedicated team of scientists in our CRO facility providing you with actionable data within weeks.

Learn more

Add PhysioMimix OOC to your lab


Harness the power of PhysioMimix OOC in your own lab with the purchase of a single- or multi-organ microphysiological system.

With a growing community of users and support from our experts, there has never been a better time to transition into 3D cell culture.

Learn more

Featured resources

Scientific publications

Biotransformation PK Graphic | immune-mediated liver injury

Integrated assessment of diclofenac biotransformation, pharmacokinetics and omics-based toxicity in a 3D human liver-immunocompetent co-culture system

Blogs

blog lung in crisis | immune-mediated liver injury

Immune-mediated DILI – Predicting the unpredictable!

Application notes

MPS Fatty Liver graphic | immune-mediated liver injury

Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury

View all Immune-mediated toxicity related resources

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Microphysiological systems for mAbs development: how do they address animal limitations? May 1, 2025
  • Why the FDA animal testing phase-out for monoclonal antibodies? May 1, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research April 29, 2025
Cyber Essentials Logo